Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1

Conditions

Urinary Bladder Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Bevacizumab 19Paclitaxel 16Carboplatin 12pembrolizumab 11liposomal doxorubicin 10Cyclophosphamide 9Specimen Handling 8Gemcitabine 8olaparib 7fludarabine 7Topotecan 7Magnetic Resonance Spectroscopy 7Taxes 5Immunoglobulin G 5Fulvestrant 5Disulfides 5niraparib 4Oxaliplatin 4Nivolumab 4Biopsy 4trastuzumab deruxtecan 3palbociclib 3mirvetuximab soravtansine 3aldesleukin 3Leucovorin 3Fluorouracil 31-dodecylpyridoxal 3ulixertinib 2nilotinib 2ipatasertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × RC48 antibody × 30 days × Clear all
NCT06003231 2026-06-01

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Seagen Inc.

Phase 2 Active not recruiting
120 enrolled
GynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡